병용요법 의약품 시장 예측(-2030년) : 유형, 제형, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Combination Therapy Drug Market is accounted for $197.2 billion in 2023 and is expected to reach $365.1 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Combination therapy is a medical treatment strategy that entails the simultaneous or sequential administration of two or more medications or therapeutic agents to treat a particular illness or medical condition. Combination treatment has applications in cancer, infectious disorders, cardiovascular issues, and more areas of medicine. The combination of the medications may maximize effectiveness while reducing negative effects.

Market Dynamics:

Driver:

Technological advancements in drug development

The field of combination therapy has been greatly improved by technological developments in drug creation, giving a number of benefits in the treatment of many medical diseases. Technological developments like genomics and molecular profiling enable combination medicines to be tailored based on a patient's particular genetic profile. This allows for individualized treatment that maximizes efficacy while minimizing negative effects based on the unique qualities of the patient and the ailment. Over the projection period, this is probably going to help the market develop.

Restraint:

Increased side effects

The chance of side effects or negative reactions may rise while taking various medications together. Patients encounter stronger medication interactions or adverse effects, which might make the therapy less tolerable. Combining medications can result in cumulative toxicity, a condition in which the body gradually builds up more of a particular chemical, perhaps resulting in organ damage or other negative effects. This is the main issue impeding market expansion.

Opportunity:

Growing awareness about the benefits

Combination treatment is the use of two or more medications to treat a specific illness or medical condition. It has a number of benefits chief among them improved therapeutic effectiveness and fewer adverse effects. Multiple medications acting synergistically to target many disease-related factors are one important advantage, which frequently results in better results. Additionally, combining medications can reduce the necessary individual dosages, decreasing adverse effects and improving patient compliance with therapy. These are the factors influencing the growth of the maket.

Threat:

Higher costs

The cost of therapy as a whole can be greatly raised by the usage of various medications. For certain individuals, especially in healthcare systems with constrained resources, this might be a barrier to access. Particularly in nations with socialized or publicly supported healthcare, the high expense of combination medicines can put a burden on healthcare systems. Governments frequently have to make difficult choices about which treatments to include in their formularies due to cost-effectiveness and financial restrictions. This is the element limiting market expansion.

COVID-19 Impact:

Clinical studies for combination treatments were being conducted when COVID-19 disturbed them. The pandemic caused several trials to be either suspended or postponed, which had an impact on the schedule for prospective medication approvals and patient access to cutting-edge therapies. The epidemic revealed weaknesses in the world's medicine supply networks. There were shortages of several combination treatment medications in some areas due to disruptions in pharmaceutical manufacture and distribution.

The diammonium glycyrrhizinate segment is expected to be the largest during the forecast period

The diammonium glycyrrhizinate segment is expected to be the largest during the forecast period. Diammonium glycyrrhizinate (DAG) is a plant growth regulator. It is naturally present in licorice plant roots, which are used in traditional Chinese medicine to cure colds and coughs. DAG has been investigated for its potential as an anti-inflammatory medication, however it failed to demonstrate any appreciable distinction from the top non-steroidal anti-inflammatory medications already on the market.

The cardiovascular disease segment is expected to have the highest CAGR during the forecast period

The cardiovascular disease segment is expected to have the highest CAGR during the forecast period. Combination treatment is a method for managing and treating several aspects of heart and vascular health. It uses a number of medications with varied modes of action. This strategy is frequently used to treat risk factors for cardiovascular disorders, such as high blood pressure, high cholesterol, and blood clot formation. Utilizing drugs like statins and antiplatelet agents is a common component of combination therapy for cardiovascular disease.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Through their joint efforts in medication discovery and development, biotechnology companies, academic institutions, and research organizations also contribute to the expansion of this industry. The desire for novel combination medicines is being driven by causes such as rising public knowledge of the advantages of combination therapy, rising rates of chronic illnesses including cancer, diabetes, and cardiovascular problems, and improvements in pharmaceutical research and development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The burden of chronic illnesses including cancer, diabetes, and cardiovascular conditions was growing throughout the area. Drug combinations were becoming increasingly important for treating complicated medical disorders. Many nations in the area were expanding their expenditures on medical research and infrastructure, which aided in the creation and uptake of combination treatment medications.

Key players in the market

Some of the key players in Combination Therapy Drug market include: WebMD LLC, CSL Ltd, Grifols S.A, Baxalta Incorporated, Octapharma AG, Kedrion S.p.A, China Biologic Products, Roche, Pfizer, Eli Lilly, Johnson & Johnson, Novartis, Gilead Sciences, AstraZeneca, Merck & Co. and Sanofi.

Key Developments:

In July 2023, Flagship Pioneering, Inc. and Pfizer Inc. announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs.

In November 2022, Arcturus Therapeutics Holdings Inc. announced a strategic collaboration with CSL Seqirus. CSL Seqirus' vaccine portfolio includes the world's second largest influenza vaccine franchise. CSL Seqirus is part of CSL Limited

In September 2022, WebMD Health Services announced a new partnership with Fern Health, a leading digital platform giving employees and health plan members the guidance and tools they need to address the underlying causes of persistent pain.

Types Covered:

• Interferon and Nucleoside Drugs
• Targeted Therapies Drugs
• Diammonium Glycyrrhizinate
• Other Types

Drug Forms Covered:

• Liquid
• Solid

Applications Covered:

• Cancer
• Cardiovascular Disease
• Immune Disease
• Other Applications

End Users Covered:

• Clinic
• Hospital
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Combination Therapy Drug Market, By Type

• 5.1 Introduction
• 5.2 Interferon and Nucleoside Drugs
• 5.3 Targeted Therapies Drugs
• 5.4 Diammonium Glycyrrhizinate
• 5.5 Other Types

6 Global Combination Therapy Drug Market, By Drug Form

• 6.1 Introduction
• 6.2 Liquid
• 6.3 Solid

7 Global Combination Therapy Drug Market, By Application

• 7.1 Introduction
• 7.2 Cancer
• 7.3 Cardiovascular Disease
• 7.4 Immune Disease
• 7.5 Other Applications

8 Global Combination Therapy Drug Market, By End User

• 8.1 Introduction
• 8.2 Clinic
• 8.3 Hospital
• 8.4 Other End Users

9 Global Combination Therapy Drug Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 WebMD LLC
• 11.2 CSL Ltd
• 11.3 Grifols S.A
• 11.4 Baxalta Incorporated
• 11.5 Octapharma AG
• 11.6 Kedrion S.p.A
• 11.7 China Biologic Products
• 11.8 Roche
• 11.9 Pfizer
• 11.10 Eli Lilly
• 11.11 Johnson & Johnson
• 11.12 Novartis
• 11.13 Gilead Sciences
• 11.14 AstraZeneca
• 11.15 Merck & Co.
• 11.16 Sanofi